In this episode of The UroGist, host Dr. Mike Louie of UroGen sits down with guest Dr. Jennifer Linehan, an Associate Professor of Urologic Oncology and Section Head of Urology Translational Research at the St. John's Cancer Institute in Santa Monica, CA to discuss the nuances of antegrade administration of an innovative treatment for low-grade upper tract urothelial cancer.
While discussing the OLYMPUS study, the episode refers to 84% durability [1] for 12 months for patients with low-grade upper tract urothelial cancer, which was found in interim data. The final durability of response data from the OLYMPUS trial for all 41 patients was 82% at 12 months. [2]
· JELMYTO Full Prescribing Information, Instructions for Pharmacy, and Instructions for Administration
· The OLYMPUS Study
· JELMYTO Instructions for Administration
· Antegrade Administration of JELMYTO
· uTRACT Jelmyto Registry – NIH National Cancer Institute
· uTRACT Jelmyto Registry – ClinicalTrials.gov
· Journal of Urologic Oncology – Joseph M Jacob, Solomon L Woldu, Jennifer Linehan, Craig Labbate, Kyle M Rose, Wade J Sexton, Isamu Tachibana, Hristos Kaimakliotis, Alan Nieder, Marc A Bjurlin, Mitchell Humphreys, Saum B Ghodoussipour, Marcus Quek, Michael O’Donnell, Brian H Eisner, Adam S Feldman, Surena F Martin, Yair Lotan, Katie S Murray
· European Urology Focus – Jennifer Linehan, Josh Gottlieb, Solomon L Woldu, Craig Labbate, Kyle Rose, Wade Sexton, Hristos Kaimakliotis, Joseph Jacob, Rian Dickstein, Alan Nieder, Marc Bjurlin, Mitchell Humphreys, Saum Ghodoussipor, Marcus Quek, Michael O’Donnell, Brian H Eisner, Adam S Feldman, Surena F Matin, Yair Lotan, Katie S Murray
[1] Lerner, Seth. Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): a prospective single-arm phase 3 trial. The Lancet Oncology, 2020
[2] Matin SF, Pierorazio PM, Kleinmann N, Gore JL, Shabsigh A, Hu B, Chamie K, Godoy G, Hubosky SG, Rivera M, O'Donnell M, Quek M, Raman JD, Knoedler JJ, Scherr D, Weight C, Weizer A, Woods M, Kaimakliotis H, Smith AB, Linehan J, Coleman J, Humphreys MR, Pak R, Lifshitz D, Verni M, Klein I, Konorty M, Strauss-Ayali D, Hakim G, Seltzer E, Schoenberg M, Lerner SP. Durability of Response to Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma Using UGN-101, a Mitomycin-Containing Reverse Thermal Gel: OLYMPUS Trial Final Report. J Urol. 2022 Apr;207(4):779-788. doi: 10.1097/JU.0000000000002350. Epub 2021 Dec 17. PMID: 34915741.
